Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,623 followers
16h
Aging is not only a societal challenge but also an #economic one. As the number of Americans over the age of 65 rises, so do the costs associated with healthcare.
Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is filled with committed researchers who are working to lighten aging's financial burden.
#GENF offers:
↗️ research focusing on #centenarian variant of the #SIRT6 gene
↗️ promising, innovative treatments for a variety of illnesses
↗️ scientific advisory board is filled with dedicated & committed researchers
Make sure to take a look at National Library of Medicines take on the economic implications of aging : htTps://loom.ly/f9analU
#aging #healthspan
Perfectly poised and primed, as the spring becomes coiled in anticipation of the next UPdate and significant move North. Gla holders:-)
Whys it struggling with the 3.3 barrier. Buys out doing sales everyday, volume was low today but its been reasonable over the last week.
Is it being held down?
Any views?
“Helping create these connections is central to our mission at Founders Forum Group as we seek to empower entrepreneurs at every stage of their journeys; with Longevity.Technology as our partner, we can forge formative alliances that propel longevity innovation.”
Big news could at anytime, and any in time for next weeks event would certainly put Genflow centre stage.
10th - 11th June 2024 - Organised by Longevity Technology who hold 3% of Genflow, the advisory panel includes Eric Verdin who sits on Genflow's Scientific Advisory Board, Aubrey de Grey who originally was a member of Genflow's SAB and Jim Mellon who was an investor in Genflow's IPO....All bodes well!!! Gla ;-)
New international event program launches to bring longevity entrepreneurs and investors together.
Founders Forum and Longevity.Technology today announced the launch of the Founders Longevity Forum, a premier event series designed to educate and connect investors with the vast potential within the longevity market.
The inaugural Founders Longevity Forum will take place at Olympia London during the renowned London Tech Week, focusing on a sector that is projected to exceed $600 billion by 2025. This partnership aims to foster meaningful connections between startups, venture capitalists (VCs), corporate venture capitalists (CVCs), family offices and CEOs leading the charge in longevity.
Brent Hoberman, Co-Founder and Executive Chair of Founders Forum Group, said: “Longevity is becoming a mega trend as science makes increased healthspans more realistic, converging with a wider shift towards preventative healthcare.
“We’ve noticed a need to connect top scientists and innovative startups with funds to help them turn their dreams into reality. By bringing together the best and brightest minds working on longevity today, we can galvanize progress in this area and transform the demographic landscape.”
Taking place on New international event program launches to bring longevity entrepreneurs and investors together.4, the Founders Longevity Forum will address the investment opportunities across the longevity space, from established longevity business models such as diagnostics, longevity clinics and supplements, through to cutting-edge longevity biotech companies poised to revolutionize the biotech industry and transform society.
The event will also benefit from an advisory panel that has decades of longevity and geroscience expertise between them; the panel includes Eric Verdin, Andrea Maier, Jim Mellon and Aubrey de Grey, with further members to be announced.
“Multiple longevity events are happening and they’re all great, but few are specifically focused on bringing more investors into this rapidly accelerating field,” said Phil Newman, Founder and CEO, Longevity.Technology.
“We plan to stage events in London, Abu Dhabi and San Francisco initially to accelerate longevity investment globally, and catalyze a wave of innovation and collaboration that will redefine the future of human health.”
“We’re keen to educate investors on the vast opportunities in longevity whilst fostering meaningful connections for startups and scaleups in this niche,” said Carolyn Dawson, CEO, Founders Forum Group.
Cutting edge science with patents pending, compelling preclinical data progressing to human clinical trials, prestigious academic partners and a leading influential and distinguished hands on Scientific Advisory Board.
Will a Major Pharma/JV partner wait for positive trial results from Genflow's Nash Human Clinical Phase 1/2 trials planned for next year, or will one move early given how hot the Nash/Liver space is right now, as well as the promise of a rapidly expanding and evolving longevity market and the compelling nature of SIRT6's profound importance and influence over multiple disease targets associated with aging. Gla ;-)
RNS Number : 7241Q
Genflow Biosciences PLC
03 June 2024
3 June 2024
Genflow Biosciences Plc
Notice of Annual General Meeting
Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting ("AGM") at 12pm on Thursday 27 June 2024 at 1 Heddon Street, London, W1B 4BT.
The Notice of the AGM ("Notice") and 2024 Form of Proxy will shortly be available on the Company's website, www.genflowbio.com, and have, where applicable, been posted to shareholders. Further details of the arrangements for this year's AGM are set out in the Notice.
As announced on 7 May 2024, the Company's Annual Report and Accounts for the year ended 31 December 2023 are also available on the website and has, where applicable, also been posted to registered shareholders.
I’m not expecting any announcement because of the conference. It would be highly unusual to do this and make a presentation although Vera is speaking tonight so it would t be breaking any market rules, I think. Anyhow, no rns and some will sell on no news. Good luck to them, but I’m here for the long haul.
Eh, scarcely a pump. A couple of new faces dropped in, predicting a further rise to 5p, but mostly people here are pretty balanced. This ain't AIM
The balance sheet is good, the progress is solid. Some people will get burned by buying high and selling low because they're getting all their info from message boards and chat groups (those people will always lose money IMO), but ultimately I think anybody getting in under 5p will see a profit eventually. Under 3p is a steal
Definitely long for moi
Good effort lol
That would be nice as the majority of shares are held very tightly for bigger and better things to come, and so any continued UPside will be no surprise as the share accumulation continues. Big news could also land at anytime as there's plenty in the pipeline, and propel the sp to a 12 month high and beyond. Gla holders...Exciting times!!! :-)))
Genf is pump of the month
Really liking Genflow on Telegram share channels
Giving it a big thumbs up
Lovely indeed Porter, the conference starts tomorrow and so it would be amazing to get news on Monday, although regardless, I'm still sure June will see a significant re-rate as important news is delivered. Gl :')
"presentation of cutting-edge and unpublished research"
It looks like quite a major event! Would be lovely for there to be a major announcement from Vera. Both US patents are now at the 3 year mark, so it would be amazing if they were both approved to coincide with the Rochester conference!
Maybe incoming news at next weeks conference from Vera's SIRT6 studies at University of Rochester. Gla ;-)
Systems Modeling, Aging Biomarkers, and Longevity Interventions
Systems Aging Gordon Research Conference
June 2 - 7, 2024
The Systems Aging GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages.
Keynote Session: Molecular Approaches in Age Reversal Research
Discussion Leader: Vera Gorbunova (University of Rochester, United States)
hTtps://www.grc.org/systems-aging-conference/2024/
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,618 followers
1d
For the first time since 2020, US life expectancy has increased.
Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is dedicated to ensuring that #healthspan grows alongside lifespan. Our groundbreaking research surrounding #SIRT6 mutations could revolutionize how we age and ensure we live healthier for longer.
Learn more about our research: htTps://loom.ly/uh0pGy8
I reckon we're going to see a decent re-rate this coming month on the back of important news and so I'd be surprised at anything sub 3p going forward...Big players are accumulating for big things to come and every chance of US institutional investors awaiting in the wings...Genflow's prospects and potential suggest the journey from small cap to mid cap is well underway. Gla :-)
My view too lile.
I got the vast majority in my isa, but some in an ordinary investment account, my plan is to keep the isa holding long term, but ditch the non isa stuff as I near CGT thresholds.
Don't want to be forced into self assessment
I'll pick up some more up at 2.6 which we will see again if things remain quiet, hopefully not going sub 2 any time soon but even then I'll just pick up more.
I'll probably offload a couple of hundred thousand shares if we hit 10 to significantly derisk my overall holding. Otherwise, I'm holding onto the bulk until the big break
Same here Porter, will not be selling any for the foreseeable. Endless multi-bag potential for life changing returns as we progress to clinical trials next year, including early acquisition/ Major JV partner. Gl :-)
Certainly seems like anything is possible for GENF at this stage. Hence why I’m sitting tight and not even tempted to risk trading a bean :)
M & A on the rise. Gla:-)
Genetic Engineering & Biotechnology News
Merck to Acquire UK Biotech EyeBio for Up to $3B, Re-Entering Eye Drug Space
May 29, 2024
Merck & Co. has agreed to acquire EyeBiotech (EyeBio) for up to $3 billion, the companies said today, in a deal that will return the buyer to the eye drug development segment it vacated about a decade ago.
Based in London, EyeBio has developed a pipeline of clinical and preclinical candidates designed to prevent and treat vision loss associated with retinal vascular leakage. EyeBio’s lead candidate Restoret™ (EYE103) is a tetravalent, tri-specific antibody agonist of the Wingless-related integration site (Wnt) signaling pathway.
https://www.genengnews.com/topics/drug-discovery/merck-to-acquire-eyebio-for-up-to-3b-re-entering-eye-drug-space/
I don’t think the main bulky trades towards the end of the day were sells and were actually buys and some weak hands fell for the bait (again) in letting panic selling set in. Most of us are here for the main event (buy out), so whatever keeps people busy in the meantime, will be what it will be :)
You can't blame those that got in at 1.5 to 2p for taking their profit at 3p if that was their strategy.
They are being swapped for holders at 3p, next profit taking at 4.5p when the new holders are 50% up me thinks